BioAffinity Technologies Valuation
| BIAF Stock | USD 0.85 0.10 13.49% |
Today, the firm appears to be undervalued. bioAffinity Technologies shows a prevailing Real Value of $2.05 per share. The current price of the firm is $0.85119998. Our model approximates the value of bioAffinity Technologies from analyzing the firm fundamentals such as Current Valuation of (3.15 M), operating margin of (1.59) %, and Return On Equity of -2.45 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting BioAffinity Technologies' valuation include:
Price Book 0.4317 | Enterprise Value | Enterprise Value Ebitda (0.21) | Price Sales 0.4979 | Enterprise Value Revenue 1.1383 |
Undervalued
Today
Please note that BioAffinity Technologies' price fluctuation is dangerous at this time. Calculation of the real value of bioAffinity Technologies is based on 3 months time horizon. Increasing BioAffinity Technologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the BioAffinity stock is determined by what a typical buyer is willing to pay for full or partial control of bioAffinity Technologies. Since BioAffinity Technologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioAffinity Stock. However, BioAffinity Technologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.85 | Real 2.05 | Target 6.0 | Hype 0.92 | Naive 0.4 |
The real value of BioAffinity Stock, also known as its intrinsic value, is the underlying worth of bioAffinity Technologies Company, which is reflected in its stock price. It is based on BioAffinity Technologies' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of BioAffinity Technologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of bioAffinity Technologies helps investors to forecast how BioAffinity stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioAffinity Technologies more accurately as focusing exclusively on BioAffinity Technologies' fundamentals will not take into account other important factors: When choosing an evaluation method for bioAffinity Technologies, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
BioAffinity Technologies Cash |
|
BioAffinity Technologies Total Value Analysis
bioAffinity Technologies is currently forecasted to have valuation of (3.15 M) with market capitalization of 3.37 M, debt of 1.5 M, and cash on hands of 214.4 K. The negative valuation of BioAffinity Technologies may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the BioAffinity Technologies fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(3.15 M) | 3.37 M | 1.5 M | 214.4 K |
BioAffinity Technologies Investor Information
The company has price-to-book (P/B) ratio of 0.43. Some equities with similar Price to Book (P/B) outperform the market in the long run. bioAffinity Technologies recorded a loss per share of 13.83. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 19th of September 2025. Based on the key indicators related to BioAffinity Technologies' liquidity, profitability, solvency, and operating efficiency, bioAffinity Technologies is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.BioAffinity Technologies Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BioAffinity Technologies has an asset utilization ratio of 143.73 percent. This implies that the Company is making $1.44 for each dollar of assets. An increasing asset utilization means that bioAffinity Technologies is more efficient with each dollar of assets it utilizes for everyday operations.BioAffinity Technologies Profitability Analysis
Based on BioAffinity Technologies' profitability indicators, bioAffinity Technologies may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess BioAffinity Technologies' ability to earn profits and add value for shareholders.Net Loss | First Reported 2020-12-31 | Previous Quarter -4.1 M | Current Value -5.1 M | Quarterly Volatility 1.7 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.58 | 0.42 |
|
|
For BioAffinity Technologies profitability analysis, we use financial ratios and fundamental drivers that measure the ability of bioAffinity Technologies to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BioAffinity Technologies utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioAffinity Technologies's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BioAffinity Technologies over time as well as its relative position and ranking within its peers.
BioAffinity Technologies Earnings per Share Projection vs Actual
By analyzing BioAffinity Technologies' earnings estimates, investors can diagnose different trends across BioAffinity Technologies' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for bioAffinity Technologies is based on EPS before non-recurring items and includes expenses related to employee stock options.BioAffinity Technologies Ownership Allocation
bioAffinity Technologies shows 3.15 percent of its outstanding shares held by insiders and 9.12 percent owned by other corporate entities.BioAffinity Technologies Profitability Analysis
The company reported the previous year's revenue of 9.36 M. Net Loss for the year was (9.04 M) with profit before overhead, payroll, taxes, and interest of 1.89 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates BioAffinity Technologies' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in BioAffinity Technologies and how it compares across the competition.
About BioAffinity Technologies Valuation
The stock valuation mechanism determines BioAffinity Technologies' current worth on a weekly basis. Our valuation model uses a comparative analysis of BioAffinity Technologies. We calculate exposure to BioAffinity Technologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioAffinity Technologies's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 3.9 M | 4.1 M | |
| Pretax Profit Margin | (0.87) | (0.91) | |
| Operating Profit Margin | (0.86) | (0.90) | |
| Net Loss | (0.87) | (0.91) | |
| Gross Profit Margin | 0.42 | 0.58 |
BioAffinity Technologies Current Valuation Indicators
Valuation refers to the process of determining the present value of bioAffinity Technologies and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value BioAffinity we look at many different elements of the entity such as BioAffinity's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as BioAffinity Technologies, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use BioAffinity Technologies' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes BioAffinity Technologies' worth.Complementary Tools for BioAffinity Stock analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Stocks Directory Find actively traded stocks across global markets |